CY2013027PI2 - NEW INSULIN DERIVATIVES - Google Patents

NEW INSULIN DERIVATIVES

Info

Publication number
CY2013027PI2
CY2013027PI2 CY2013027C CY2013027PC CY2013027PI2 CY 2013027P I2 CY2013027P I2 CY 2013027PI2 CY 2013027 C CY2013027 C CY 2013027C CY 2013027P C CY2013027P C CY 2013027PC CY 2013027P I2 CY2013027P I2 CY 2013027PI2
Authority
CY
Cyprus
Prior art keywords
insulin derivatives
new insulin
new
derivatives
insulin
Prior art date
Application number
CY2013027C
Other languages
Greek (el)
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of CY2013027PI1 publication Critical patent/CY2013027PI1/en
Publication of CY2013027PI2 publication Critical patent/CY2013027PI2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CY2013027C 2003-08-05 2013-07-04 NEW INSULIN DERIVATIVES CY2013027PI2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200301129 2003-08-05
US49545103P 2003-08-14 2003-08-14
EP04739008A EP1660531A2 (en) 2003-08-05 2004-07-22 Novel insulin derivatives

Publications (2)

Publication Number Publication Date
CY2013027PI1 CY2013027PI1 (en) 2015-11-04
CY2013027PI2 true CY2013027PI2 (en) 2015-11-04

Family

ID=34117520

Family Applications (5)

Application Number Title Priority Date Filing Date
CY20131100259T CY1113850T1 (en) 2003-08-05 2013-03-28 NEW INSULIN PRODUCERS
CY2013027C CY2013027PI2 (en) 2003-08-05 2013-07-04 NEW INSULIN DERIVATIVES
CY2013029C CY2013029PI2 (en) 2003-08-05 2013-07-08 NEW INSULIN DERIVATIVES
CY2013029C CY2013029I2 (en) 2003-08-05 2023-12-28 NEW INSULIN DERIVATIVES
CY2013027C CY2013027I1 (en) 2003-08-05 2024-01-31 NEW INSULIN DERIVATIVES

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20131100259T CY1113850T1 (en) 2003-08-05 2013-03-28 NEW INSULIN PRODUCERS

Family Applications After (3)

Application Number Title Priority Date Filing Date
CY2013029C CY2013029PI2 (en) 2003-08-05 2013-07-08 NEW INSULIN DERIVATIVES
CY2013029C CY2013029I2 (en) 2003-08-05 2023-12-28 NEW INSULIN DERIVATIVES
CY2013027C CY2013027I1 (en) 2003-08-05 2024-01-31 NEW INSULIN DERIVATIVES

Country Status (18)

Country Link
US (3) US7615532B2 (en)
EP (3) EP2107069B1 (en)
JP (1) JP4463814B2 (en)
KR (1) KR101159559B1 (en)
AU (2) AU2004261353B2 (en)
BE (2) BE2013C035I2 (en)
BR (1) BRPI0413276B8 (en)
CA (1) CA2531988C (en)
CY (5) CY1113850T1 (en)
FR (2) FR13C0035I2 (en)
HU (1) HUS1300033I1 (en)
IL (1) IL172980A (en)
LU (2) LU92213I2 (en)
MX (1) MXPA06001283A (en)
NO (5) NO340925B1 (en)
PL (1) PL2107069T3 (en)
RU (1) RU2518460C2 (en)
WO (1) WO2005012347A2 (en)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241019A1 (en) * 2003-07-25 2006-10-26 Bridon Dominique P Long lasting insulin derivatives and methods thereof
JP4463814B2 (en) 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ New insulin derivatives
WO2006082205A1 (en) * 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
EP2256130B1 (en) * 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
ATE519780T1 (en) * 2005-12-28 2011-08-15 Novo Nordisk As COMPOSITIONS CONTAINING ACYLATED INSULIN AND ZINC AND METHOD FOR PRODUCING THESE COMPOSITIONS
WO2007096431A1 (en) * 2006-02-27 2007-08-30 Novo Nordisk A/S Insulin derivatives
WO2007104736A2 (en) * 2006-03-13 2007-09-20 Novo Nordisk A/S Acylated single chain insulin
EP2015722B1 (en) 2006-04-28 2016-11-16 Avent, Inc. Antimicrobial site dressings
AU2007247109B2 (en) 2006-05-09 2012-03-15 Novo Nordisk A/S Insulin derivative
CN101437849B (en) * 2006-05-09 2015-09-30 诺沃-诺迪斯克有限公司 Insulin derivatives
US8796205B2 (en) 2006-05-09 2014-08-05 Novo Nordisk A/S Insulin derivative
JP5097900B2 (en) * 2006-06-27 2012-12-12 独立行政法人物質・材料研究機構 Method for producing active ester of organic acid or derivative thereof
EP2049149B1 (en) 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylated extended insulins
DK2074141T3 (en) 2006-09-22 2016-11-28 Novo Nordisk As The protease resistant insulin analogues.
JP5496082B2 (en) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス Method for drying protein composition, dry protein composition, and pharmaceutical composition containing dry protein
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
WO2008145730A1 (en) * 2007-06-01 2008-12-04 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
AU2008288413B2 (en) 2007-08-15 2013-09-26 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
JP5721432B2 (en) * 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス Insulin having an acyl moiety containing an amino acid-containing alkylene glycol repeating unit
CN101157725B (en) * 2007-10-24 2012-07-25 中国药科大学 Preparation method of human insulin analogue and usage thereof
WO2009060071A1 (en) 2007-11-08 2009-05-14 Novo Nordisk A/S Insulin derivative
MX2010005245A (en) 2007-11-16 2010-06-01 Novo Nordisk As Pharmaceutical compositions containing insulin and an insulinotropic peptide.
CN101970477B (en) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 Protease-stabilized insulin analogues
EP2910569B1 (en) 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
WO2010029159A1 (en) 2008-09-12 2010-03-18 Novo Nordisk A/S Method of acylating a peptide or protein
EP2352513B1 (en) * 2008-10-30 2016-09-14 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
RU2525393C2 (en) 2009-01-23 2014-08-10 Ново Нордиск А/С Fgf21 derivatives with albumin binding agent a-b-c-d-e- and their application
CN102666579A (en) 2009-10-30 2012-09-12 诺沃—诺迪斯克有限公司 Derivatives of calcitonin gene-related peptide
JP5908847B2 (en) * 2010-01-12 2016-04-26 ノヴォ ノルディスク アー／エス Pharmaceutical composition for oral administration of insulin peptides
WO2011101277A1 (en) 2010-02-16 2011-08-25 Novo Nordisk A/S Conjugated proteins
ES2582590T3 (en) 2010-02-16 2016-09-13 Novo Nordisk A/S Purification method
WO2011141407A1 (en) 2010-05-10 2011-11-17 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
WO2011146973A1 (en) 2010-05-25 2011-12-01 Monash University Insulin analogues
EP2585483A1 (en) 2010-06-23 2013-05-01 Novo Nordisk A/S Human insulin containing additional disulfide bonds
CN104693302A (en) 2010-06-23 2015-06-10 诺沃—诺迪斯克有限公司 Insulin derivatives containing additional disulfide bonds
EP2585484A1 (en) 2010-06-23 2013-05-01 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
CN103154024A (en) 2010-10-15 2013-06-12 诺沃—诺迪斯克有限公司 Novel N-terminally modified insulin derivatives
RU2013123515A (en) 2010-10-27 2014-12-10 Ново Нордиск А/С DIABETES TREATMENT USING INSULIN INJECTIONS INJECTED WITH VARIOUS INTERVALS
RS59423B1 (en) 2010-10-27 2019-11-29 Novo Nordisk As Treating diabetes melitus using insulin injections administered with varying injection intervals
WO2012080320A1 (en) 2010-12-14 2012-06-21 Novo Nordisk A/S Fast-acting insulin in combination with long-acting insulin
CN103370075A (en) 2011-02-15 2013-10-23 诺沃—诺迪斯克有限公司 Long-acting IL-1 receptor antagonists
KR20140020292A (en) * 2011-03-28 2014-02-18 노보 노르디스크 에이/에스 Novel glucagon analogues
JP6030630B2 (en) 2011-04-14 2016-11-24 ノヴォ ノルディスク アー／エス Fatty acylated amino acids for oral peptide delivery
EP2720711A1 (en) 2011-06-15 2014-04-23 Novo Nordisk A/S Multi substituted insulins
US8541368B2 (en) 2011-09-23 2013-09-24 Novo Nordisk A/S Glucagon analogues
RU2014127270A (en) * 2011-12-15 2016-02-10 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. ANALOGUE OF HUMAN INSULIN AND ITS Acylated Derivative
EP2794648A1 (en) 2011-12-21 2014-10-29 Novo Nordisk A/S N-terminally modified insulin derivatives
BR112014025132A2 (en) 2012-04-11 2017-07-11 Novo Nordisk As insulin formulations
US20160031962A1 (en) * 2012-04-20 2016-02-04 Kleomenis K. Barlos Solid phase peptide synthesis of insulin using side chain achored lysine
BR112014026442A8 (en) 2012-05-01 2018-01-16 Novo Nordisk As combination to achieve glycemic control, its use, and pharmaceutical composition.
WO2014009316A1 (en) 2012-07-09 2014-01-16 Novo Nordisk A/S Novel use of insulin derivatives
UA116217C2 (en) 2012-10-09 2018-02-26 Санофі Exendin-4 derivatives as dual glp1/glucagon agonists
US20150265710A1 (en) 2012-10-17 2015-09-24 Novo Nordisk A/S Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery
MX360317B (en) 2012-12-21 2018-10-29 Sanofi Sa Functionalized exendin-4 derivatives.
CN105188736A (en) * 2013-03-20 2015-12-23 诺和诺德股份有限公司 Insulin dosing regimen
RS59124B1 (en) 2013-04-18 2019-09-30 Novo Nordisk As Stable, protracted glp-1/glucagon receptor co-agonists for medical use
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
GB201315335D0 (en) 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
CA2926701A1 (en) 2013-10-07 2015-04-16 Novo Nordisk A/S Novel derivative of an insulin analogue
FR3013049B1 (en) 2013-11-14 2015-11-13 You-Ping Chan ANALOGUE OF INSULIN GLARGINE
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
CN106029088A (en) 2014-02-18 2016-10-12 诺和诺德股份有限公司 Stable glucagon analogs and use for treating hypoglycemia
AR099569A1 (en) 2014-02-28 2016-08-03 Novo Nordisk As INSULIN DERIVATIVES AND THE MEDICAL USES OF THESE
TW201625669A (en) 2014-04-07 2016-07-16 賽諾菲公司 Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4
TW201625668A (en) 2014-04-07 2016-07-16 賽諾菲公司 Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
TW201625670A (en) 2014-04-07 2016-07-16 賽諾菲公司 Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4
EP3151852A1 (en) 2014-06-04 2017-04-12 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AR105319A1 (en) 2015-06-05 2017-09-27 Sanofi Sa PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR
TW201706291A (en) 2015-07-10 2017-02-16 賽諾菲公司 New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists
US20180244743A1 (en) 2015-08-25 2018-08-30 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
WO2017032795A1 (en) 2015-08-25 2017-03-02 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
CN114478747B (en) 2016-08-02 2024-06-14 江苏恒瑞医药股份有限公司 Acylated derivatives of human insulin or analogues thereof
WO2018096164A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
JP2019535791A (en) 2016-11-28 2019-12-12 ノヴォ ノルディスク アー／エス Insulin degludec for improved glycemic control and reduction of acute and long-term diabetic complications
EP3544683A1 (en) 2016-11-28 2019-10-02 Novo Nordisk A/S Insulin degludec in cardiovascular conditions
SI3554534T1 (en) 2016-12-16 2021-09-30 Novo Nordisk A/S Insulin containing pharmaceutical compositions
JOP20190273A1 (en) * 2017-05-26 2019-11-24 Lilly Co Eli Insulin treated with basil complex
JP2021513330A (en) 2018-02-09 2021-05-27 江蘇恒瑞医薬股▲ふん▼有限公司 Human insulin analog codon-optimized precursor gene and signal peptide gene
US20210198311A1 (en) 2018-05-24 2021-07-01 Jiangsu Hengrui Medicine Co., Ltd. Method for preparing precursor of recombinant human insulin or analogue thereof
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
JP7410891B2 (en) 2018-06-26 2024-01-10 ノボ・ノルデイスク・エー／エス System providing dosing recommendations for basal insulin titration
KR102666154B1 (en) 2018-08-08 2024-05-20 주식회사 대웅제약 Long-acting Insulin Analog and Derivatives Thereof
KR20200080748A (en) 2018-12-27 2020-07-07 주식회사 폴루스 A Method for Purifying Proinsulin Using Anion Exchange Chromatography
KR20200080747A (en) 2018-12-27 2020-07-07 주식회사 폴루스 An Enzymatic Conversion Composition for Producing Insulin from Proinsulin and a Method for Producing Insulin from Proinsulin Using the Same
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
TW202434620A (en) 2019-07-31 2024-09-01 美商美國禮來大藥廠 Relaxin analogs and methods of using the same
CN118420743A (en) 2019-12-30 2024-08-02 甘李药业股份有限公司 Insulin derivatives
UA129395C2 (en) 2020-05-15 2025-04-09 Елі Ліллі Енд Компані Extended time action acylated insulin compounds
CN113773398B (en) * 2020-06-10 2023-05-23 宁波鲲鹏生物科技有限公司 De-glu insulin derivative and application thereof
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
US20250000948A1 (en) 2021-11-15 2025-01-02 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023143458A1 (en) 2022-01-28 2023-08-03 甘李药业股份有限公司 Acylated insulin
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
WO2025104600A1 (en) * 2023-11-15 2025-05-22 Ambio, Inc. Insulin analogs for the treatment of human metabolic disorder and disease

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (en) 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Process for the preparation of insulin solutions
GB1042194A (en) 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
FI78616C (en) * 1982-02-05 1989-09-11 Novo Industri As Process for preparing an infused stabilized insulin solution having an elevated zinc content
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
JPH01254699A (en) 1988-04-05 1989-10-11 Kodama Kk Insulin derivative and use thereof
DE3827533A1 (en) * 1988-08-13 1990-02-15 Hoechst Ag PHARMACEUTICAL PREPARATION FOR TREATING THE DIABETES MELLITUS
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
IT1240314B (en) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. STABILIZED AQUEOUS FORMULATIONS OF SMALL PEPTIDES.
DE69019534T2 (en) 1989-12-21 1995-09-21 Novonordisk As INSULIN PREPARATIONS CONTAINING NICOTIC ACID OR NICOTINAMIDE.
DK45590D0 (en) 1990-02-21 1990-02-21 Novo Nordisk As
JP3193398B2 (en) 1991-07-23 2001-07-30 サンデン株式会社 Showcase
JP2950617B2 (en) 1991-12-20 1999-09-20 ノボ ノルディスク アクティーゼルスカブ Stabilized pharmaceutical formulation comprising growth hormone and histidine
EP1132404A3 (en) * 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
WO1996010417A1 (en) 1994-10-04 1996-04-11 Novo Nordisk A/S PREPARATIONS CONTAINING AspB28 HUMAN INSULIN AND NICOTINAMIDE
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5830999A (en) * 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
DE69629210T2 (en) 1995-03-17 2004-04-22 Novo Nordisk A/S INSULINABKÖMMLINGE
DK2275119T3 (en) 1995-07-27 2013-11-11 Genentech Inc Stable, isotonic lyophilized protein formulation
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5898267A (en) * 1996-04-10 1999-04-27 Mcdermott; Kevin Parabolic axial lighting device
US5866538A (en) * 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
WO1998002460A1 (en) * 1996-07-11 1998-01-22 Novo Nordisk A/S Selective acylation method
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
DK0821006T3 (en) * 1996-07-26 2004-08-16 Aventis Pharma Gmbh Insulin derivatives with increased zinc binding
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
JP2001518915A (en) 1997-03-20 2001-10-16 ノボ ノルディスク アクティーゼルスカブ Preparation of therapeutic powder by co-precipitation of insulin and absorption enhancer
ATE219942T1 (en) 1997-03-20 2002-07-15 Novo Nordisk As THERAPEUTIC POWDER FORMULATION FOR PULMONARY USE CONTAINING CRYSTALLINE INSULIN
HUP0000547A3 (en) * 1997-03-20 2002-11-28 Novo Nordisk As Zinc free insulin crystals for use in pulmonary compositions
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
SI0884053T1 (en) 1997-06-13 2003-02-28 Eli Lilly And Company Stable insulin formulations
US6451762B1 (en) * 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
US20020155994A1 (en) * 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
ID24890A (en) 1997-10-24 2000-08-31 Lilly Co Eli INSULIN COMPOSITIONS THAT CANNOT BE SOLUTED
HUP0004096A3 (en) * 1997-10-24 2001-12-28 Novo Nordisk As Aggregates of human insulin derivatives and pharmaceutical compositions comprising thereof
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
CO4970787A1 (en) * 1997-12-23 2000-11-07 Lilly Co Eli INSOLUBLE COMPOSITIONS OF INSULIN AND INSULIN DERIVATIVES THAT CONTROL BLOOD GLUCOSE
WO1999034821A1 (en) * 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
DE69920767T2 (en) 1998-10-16 2006-02-02 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary administration
WO2000048635A1 (en) * 1999-02-22 2000-08-24 Baxter International Inc. Novel albumin-free factor viii formulations
AU4450700A (en) 1999-04-27 2000-11-10 Eli Lilly And Company Insulin crystals for pulmonary administration
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DE10022092A1 (en) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilized protein preparation and process for its preparation
US6652886B2 (en) * 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10114178A1 (en) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinc-free and low-zinc insulin preparations with improved stability
DE60224284T2 (en) 2001-06-28 2008-12-18 Novo Nordisk A/S STABLE FORMULATION OF MODIFIED GLP-1
HUP0700126A2 (en) 2001-12-20 2007-06-28 Lilly Co Eli Insulin molecule having protracted time action
US8003605B2 (en) * 2002-03-13 2011-08-23 Novo Nordisk A/S Minimising body weight gain in insulin treatment
ATE496064T1 (en) * 2002-05-07 2011-02-15 Novo Nordisk As SOLUBLE FORMULATIONS CONTAINING MONOMERIC INSULIN AND ACYLATED INSULIN
US20050232899A1 (en) * 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en) * 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (en) 2002-08-23 2006-08-25 (주)헬릭서 Health food comprising the extract of Actinidia arguta and related species for the prevention and improvement of allergic disease and non-allergic inflammatory disease
CA2502378A1 (en) 2002-10-29 2004-05-13 Alza Corporation Stabilized, solid-state polypeptide particles
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
CA2515294A1 (en) 2003-02-07 2004-08-19 Ajinomoto Co., Inc. Therapeutic agents for diabetes
ATE473279T1 (en) 2003-02-19 2010-07-15 Novartis Pharma Gmbh GLYCOPROTEIN ANTIGEN SIMA135 EXPRESSED IN METASTATIC HUMAN TUMOR CELLS
JP2006519252A (en) * 2003-03-04 2006-08-24 ザ・テクノロジー・デヴェロップメント・カンパニー・リミテッド Drug delivery systems and cell therapy
JP4658041B2 (en) 2003-06-25 2011-03-23 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Liquid composition of factor VII polypeptide
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
JP4463814B2 (en) * 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ New insulin derivatives
SI2107069T1 (en) 2003-08-05 2013-04-30 Novo Nordisk A/S Novel insulin derivatives
CA2534028A1 (en) 2003-08-14 2005-02-24 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
EP1663295A2 (en) 2003-09-01 2006-06-07 Novo Nordisk A/S Stable formulations of peptides
ES2229931B1 (en) * 2003-10-03 2006-01-16 Grifols, S.A. BILOGICALLY STABLE LIQUID COMPOSITION OF FVIII, FVW OR HUMAN FVIII / FVW COMPLEX.
WO2005047508A1 (en) * 2003-11-14 2005-05-26 Novo Nordisk A/S Processes for making acylated insulin
BRPI0418115A (en) 2003-12-23 2007-04-17 Pharmacia Corp stable liquid growth hormone formulation
JP5022213B2 (en) 2004-03-12 2012-09-12 バイオデル， インコーポレイテッド Rapidly acting drug delivery composition
BRPI0510527A (en) 2004-06-01 2007-10-30 Ares Trading Sa protein stabilization method
BRPI0513332A (en) 2004-08-12 2008-05-06 Schering Corp stable pegylated interferon formulation
SI1778723T1 (en) 2004-08-17 2013-02-28 Regeneron Pharmaceuticals, Inc. Il-1 antagonist formulations
ES2575984T3 (en) 2004-11-12 2016-07-04 Novo Nordisk A/S Stable formulations of peptides containing an acylated GLP-1 analogue and a basal insulin
WO2006053906A1 (en) 2004-11-22 2006-05-26 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
EP1838290A2 (en) 2005-01-21 2007-10-03 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
EP2256130B1 (en) * 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
ATE519780T1 (en) 2005-12-28 2011-08-15 Novo Nordisk As COMPOSITIONS CONTAINING ACYLATED INSULIN AND ZINC AND METHOD FOR PRODUCING THESE COMPOSITIONS
WO2007096431A1 (en) * 2006-02-27 2007-08-30 Novo Nordisk A/S Insulin derivatives
CA2649109A1 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
AU2007247109B2 (en) * 2006-05-09 2012-03-15 Novo Nordisk A/S Insulin derivative
US9034818B2 (en) * 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
MX2010005245A (en) * 2007-11-16 2010-06-01 Novo Nordisk As Pharmaceutical compositions containing insulin and an insulinotropic peptide.
TWI451876B (en) * 2008-06-13 2014-09-11 Lilly Co Eli Pegylated insulin lispro compounds

Also Published As

Publication number Publication date
CA2531988A1 (en) 2005-02-10
EP2107069B1 (en) 2013-01-16
US20060183668A1 (en) 2006-08-17
NO2024003I1 (en) 2024-01-16
CY2013027PI1 (en) 2015-11-04
BE2013C035I2 (en) 2023-12-14
KR101159559B1 (en) 2012-06-26
NO2018002I1 (en) 2018-01-11
US7615532B2 (en) 2009-11-10
AU2004261353B2 (en) 2009-12-10
US8828923B2 (en) 2014-09-09
LU92226I2 (en) 2015-04-29
CY2013027I2 (en) 2024-09-20
CY2013029PI1 (en) 2015-11-04
MXPA06001283A (en) 2006-04-11
NO2018002I2 (en) 2018-08-20
PL2107069T3 (en) 2013-06-28
AU2010200497B2 (en) 2014-10-23
RU2008152033A (en) 2010-07-10
NO340925B1 (en) 2017-07-17
LU92213I9 (en) 2018-11-19
EP2264065B1 (en) 2017-03-08
CY2013027I1 (en) 2024-09-20
NO2024004I1 (en) 2024-01-16
HUS1300033I1 (en) 2016-08-29
US20100009899A1 (en) 2010-01-14
BE2013C038I2 (en) 2023-12-14
CY2013029I1 (en) 2024-09-20
FR13C0035I1 (en) 2013-08-09
EP2107069A3 (en) 2009-11-25
LU92226I9 (en) 2018-11-19
NO2018003I1 (en) 2018-01-11
US20140349925A1 (en) 2014-11-27
CA2531988C (en) 2016-06-28
LU92213I2 (en) 2013-08-23
JP4463814B2 (en) 2010-05-19
RU2518460C2 (en) 2014-06-10
EP2107069A2 (en) 2009-10-07
EP2264065A2 (en) 2010-12-22
WO2005012347A2 (en) 2005-02-10
BRPI0413276A (en) 2006-10-10
FR13C0035I2 (en) 2014-03-07
BRPI0413276B8 (en) 2021-05-25
WO2005012347A3 (en) 2005-04-14
CY2013029PI2 (en) 2015-11-04
AU2004261353A1 (en) 2005-02-10
EP1660531A2 (en) 2006-05-31
EP2264065A3 (en) 2011-07-27
NO20061026L (en) 2006-03-02
IL172980A0 (en) 2006-06-11
IL172980A (en) 2013-10-31
BRPI0413276B1 (en) 2020-03-03
JP2007523881A (en) 2007-08-23
KR20060132543A (en) 2006-12-21
CY2013029I2 (en) 2024-09-20
CY1113850T1 (en) 2015-11-04
FR13C0038I1 (en) 2013-08-09
AU2010200497A1 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
CY2013027I2 (en) NEW INSULIN DERIVATIVES
DK1594840T3 (en) Piperidine-benzenesulfonamide derivatives
CY2015036I2 (en) NEW OXAZOLIDINONE DERIVATIVES
ATE420066T1 (en) AMIDOACETONITRIL DERIVATIVES
ATE352550T1 (en) CHINAZOLINE DERIVATIVES
DK2609947T3 (en) Plaster-like infusion set
IS8108A (en) New compounds
DE602004017700D1 (en) TRANSMUKOSEN ADMINISTRATION
IS8364A (en) N-thiazol-2-yl-benzamide derivatives
ATE395345T1 (en) IMIDAZOLE-4-YL-ETHYNYL-PYRIDINE DERIVATIVES
IS2656B (en) New besimidasol derivatives
IS8228A (en) New acetidine compounds
DK2107069T3 (en) New insulin derivatives
EP1661594A4 (en) SYRINGE
IS8292A (en) New compounds
DE602004019555D1 (en) HETEROCYCLIC 7-AMINOALKYLIDENYLCHINOLONE AND -NAPHTHYRIDONE
ATE449064T1 (en) AMIDOACETONITRIL DERIVATIVES
IS8045A (en) Purin-6-one derivatives
FI20021817A7 (en) Cannula
UA6623S (en) SYRINGE
FI20030224A0 (en) New pharmaceutical uses
SE0301797D0 (en) New use V
SE0300106D0 (en) New use
SE0302332D0 (en) New use I
IS8301A (en) New Fusic Acid Derivatives